[SCHEDULE 13G/A] Insulet Corporation SEC Filing

Rhea-AI Filing Summary

Capital Research Global Investors reports beneficial ownership of 4,736,127 shares of Insulet Corporation, equal to 6.7% of the company's outstanding common stock. The filing shows sole voting power for 4,730,490 shares and sole dispositive power for 4,736,127 shares, with no shared voting or dispositive authority reported.

The statement classifies the filer as an investment adviser and includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. This is a routine institutional ownership disclosure reflecting a material passive stake above the 5% threshold.

Positive

• Material institutional stake: CRGI beneficially owns 4,736,127 shares (6.7%), crossing the 5% reporting threshold and signaling investor confidence.
• Clear control of reported shares: The filing shows sole voting power for 4,730,490 shares and sole dispositive power for 4,736,127 shares, with no shared authority reported.

Negative

• None.

Insights

Financial Analyst

TL;DR: CRGI holds a material passive stake of 6.7% in Insulet; filing is routine and disclaims intent to influence control.

Capital Research Global Investors reports beneficial ownership of 4,736,127 shares, representing 6.7% of Insulet. The split between sole voting power (4,730,490) and sole dispositive power (4,736,127) suggests centralized control over voting and disposition within CRGI-managed accounts. Because the filing is a Schedule 13G/A and includes a certification that holdings are in the ordinary course of business and not intended to change control, this should be viewed as disclosure of a significant passive institutional stake rather than an activist move.

Corporate Governance Expert

TL;DR: A >5% Schedule 13G/A signals notable institutional ownership but explicitly denies any intent to influence corporate control.

The filing identifies the reporting person as an investment adviser and reports no shared voting or dispositive power. The certification language present is standard for passive 13G reporting and reduces immediate governance risk of an unsolicited control campaign. Investors should note the materiality of a single institution holding 6.7%, but the document provides no indication of director nominations or coordination with other holders.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 11)

Insulet Corp.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

45784P101

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 45784P101

1

Names of Reporting Persons

Capital Research Global Investors

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,730,490.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,736,127.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,736,127.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.7 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Insulet Corp.
(b)	Address of issuer's principal executive offices: 100 Nagog Park, Acton, MA 01720, United States of America
Item 2.
(a)	Name of person filing: Capital Research Global Investors
(b)	Address or principal business office or, if none, residence: 333 South Hope Street, 55th Fl, Los Angeles, CA 90071
(c)	Citizenship: N/A
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 45784P101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 4,736,127 ** **Capital Research Global Investors ("CRGI") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited (together with CRMC, the "investment management entities"). CRGI's divisions of each of the investment management entities collectively provide investment management services under the name "Capital Research Global Investors." CRGI is deemed to be the beneficial owner of 4,736,127 shares or 6.7% of the 70,374,923 shares believed to be outstanding.
(b)	Percent of class: 6.7 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 4,730,490
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 4,736,127
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Capital Research Global Investors

Signature:	Jae Won Chung
Name/Title:	Vice President and Senior Counsel II, Capital Research and Management Company
Date:	08/05/2025

FAQ

How many Insulet (PODD) shares does Capital Research Global Investors report owning?

The filing reports beneficial ownership of 4,736,127 shares of Insulet common stock, representing 6.7% of the outstanding shares.

Does CRGI have voting power over its Insulet (PODD) shares?

Yes. The filing shows sole voting power for 4,730,490 shares and no shared voting power.

Is the Schedule 13G/A filing indicative of an attempt to take control of Insulet (PODD)?

No. The filer certifies the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer.

What type of reporting person filed the Schedule 13G/A for PODD?

The filing classifies the reporting person as an investment adviser (IA) operating under the name Capital Research Global Investors.

Who signed the filing on behalf of Capital Research Global Investors?

The filing is signed by Jae Won Chung, identified as Vice President and Senior Counsel II at Capital Research and Management Company.